CS-206 in Patients With Sickle Cell Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CS-206 in Patients With Sickle Cell Disease — Stella

Recruiting

Back to Sickle Cell Disease trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi

Key details

Phase

Very early testing

Sponsor

CorrectSequence Therapeutics Co., Ltd

Collaborators

First Affiliated Hospital of Guangxi Medical University

Enrollment target

~5 participants

Started

September 2024

Primary completion

December 2026

Age range

12 Years – 35 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov